Home » Topics » Regulatory » EMA

EMA
RSS

CHMP grants positive opinion for Alecensa for the treatment of NSCLC

Dec. 20, 2016

CHMP grants positive opinion to acknowledge that Jardiance reduces the risk of CV death

Dec. 20, 2016

Merck & Co.'s Keytruda gets positive opinion from EMA's CHMP

Dec. 19, 2016

EMA committee recommends approval of baricitinib for RA

Dec. 19, 2016

Novartis' Votubia receives positive opinion in E.U.

Dec. 19, 2016

EMA's CHMP backs approval of canakinumab in periodic fever syndromes

Dec. 19, 2016

Gedeon Richter withdraws European applications for biosimilar pegfilgrastim

Dec. 19, 2016

Minoryx Therapeutics' lead candidate granted orphan drug designation in Europe

Dec. 19, 2016

EMA grants orphan designation to REGN-2477 for fibrodysplasia ossificans progressiva

Dec. 16, 2016

CM-4620 receives EMA orphan designation for acute pancreatitis

Dec. 15, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...